Researchers at the American Cancer Society and Emory University’s Rollins School of Public Health found eight molecules in stored blood that tracked both with air pollution exposure and with a later lung cancer diagnosis. The study, published August 11 in Nature Communications, used plasma collected from 1,357 people who were cancer free on the day their blood was drawn, in some cases years before cancer appeared.
Key takeaways
- Eight blood metabolites were linked to both air pollution exposure and later lung cancer risk. Four of them appeared to carry part of the effect of particulate matter and ozone.
- In one of the two cohorts, the blood was drawn a median of 7 years before diagnosis.
- This is not a test you can order, and it does not change screening today. It does sharpen an old problem: US screening rules are built around smoking history, and air pollution is not in them at all.
What the study found
The team drew on two American Cancer Society cohorts, the Cancer Prevention Study II Nutrition Cohort and CPS-3. Of the 1,357 participants, 1,052 came from CPS-II and 305 from CPS-3. All were free of cancer when their blood was banked. Over follow up, 671 of them were diagnosed with lung cancer.
Among CPS-II participants who developed lung cancer, the median gap between blood draw and diagnosis was 7 years, with half of cases falling between 3 and 10 years. In CPS-3 the median gap was 2 years.
Researchers estimated residential levels of six major air pollutants at the time of each blood draw, then profiled more than 1,100 metabolites in the samples. Of the 1,138 metabolites that passed quality checks, 522 were associated with at least one pollutant. Carbon monoxide and fine particulate matter accounted for the most hits, at 276 and 261 metabolites.
Eight of those were also associated with lung cancer risk. Four of them, including gamma-glutamylglutamine and phenylacetylglutamate, statistically mediated the link for particulate matter and ozone. They behaved like middle steps on the road from breathing polluted air to developing cancer. The metabolites clustered in pathways tied to inflammation, oxidative stress, detoxification and energy handling, the same inflammation and oxidation machinery that shows up when the body is under sustained stress.
Dr. Kumar’s take
The coverage is running with early detection. That framing is years ahead of the data.
Start with the statistical threshold. The authors used a false discovery rate cutoff of 0.2, meaning up to about one in five of the flagged findings could be a false alarm. That is reasonable for a study designed to generate hypotheses. It is not the standard you would want behind a test that tells someone they may be growing a tumor.
This was also a nested case control study, so the ratio of cancers to non-cancers in the sample was set by the researchers and does not reflect anyone’s real world odds. The associations were reported as statistical coefficients, not as a percentage change in risk, so there is no way to say how much any of these molecules raises or lowers a person’s chances. In CPS-II, 96% of participants were white, which narrows how far the pattern can be extended. And a blood marker found years ahead of disease is not automatically useful, a lesson other pre-diagnostic blood markers have already taught.
The part worth arguing about is policy. Eligibility for lung cancer screening in the US turns on smoking history. Exposure is not a criterion. As study co-senior author Donghai Liang, PhD, put it, “more than half of lung cancers are diagnosed among people who never smoke or who have ever smoked but are ineligible for lung cancer screening.”
So the biology this paper describes belongs largely to people the system does not look for. Co-senior author Ying Wang, PhD, of the American Cancer Society noted that the link between outdoor air pollution and lung cancer “is often strongest among people who have never smoked.” Until risk models account for where someone has lived and breathed, better biomarkers will keep pointing at a group no one is scanning.
What it means for you
There is nothing to ask for at the lab. No clinic offers this panel, and none should yet.
What is actionable is exposure. Long-term outdoor air pollution is a recognized cause of lung cancer, and where you live and how you filter your indoor air are the levers you control. Local air quality readings, filtration on bad days, and less time near heavy traffic during pollution spikes are all reasonable.
The other practical point is for never-smokers. A persistent cough, hoarseness, or unexplained shortness of breath deserves a workup on its own merits. “You don’t smoke” is a reassurance, not a diagnosis.